Compounds > 3-[1-[[1-(4-methylphenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
Page last updated: 2024-08-03 08:50:51

3-[1-[[1-(4-methylphenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one

Description

3-[1-[[1-(4-methylphenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID23612552
CHEMBL ID1366039
CHEBI ID93564

Synonyms (28)

Synonym
MLS001116074 ,
smr000625852
MLS-0368126.0001
ml191
931695-79-3
ml-191
AKOS001524803
HMS2954I11
MLS003183111
CCG-152883
CHEMBL1366039
5-phenyl-3-[1-[1-(p-tolyl)cyclopropanecarbonyl]-4-piperidyl]-1,3,4-oxadiazol-2-one
3-[1-[[1-(4-methylphenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
bdbm61596
3-[1-[1-(4-methylphenyl)cyclopropyl]carbonylpiperidin-4-yl]-5-phenyl-1,3,4-oxadiazol-2-one
3-[1-[1-(4-methylphenyl)cyclopropanecarbonyl]piperidin-4-yl]-5-phenyl-1,3,4-oxadiazol-2-one
cid_23612552
CHEBI:93564
3-{1-[1-(4-methylphenyl)cyclopropanecarbonyl]piperidin-4-yl}-5-phenyl-2,3-dihydro-1,3,4-oxadiazol-2-one
NCGC00386924-03
Q27165259
AS-16668
EX-A4824
3-[1-[1-(4-methylphenyl)cyclo propanecarbonyl]piperidin-4-yl]-5-phenyl-1,3,4-oxadiazol-2-one
HY-111083
CS-0034184
AC-36609
5-PHENYL-3-(1-(1-(P-TOLYL)CYCLOPROPANE-1-CARBONYL)PIPERIDIN-4-YL)-1,3,4-OXADIAZOL-2(3H)-ONE

Drug Classes (1)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency25.1189AID485341
glp-1 receptor, partialHomo sapiens (human)Potency28.1838AID624417
TDP1 proteinHomo sapiens (human)Potency19.4622AID686978; AID686979
Smad3Homo sapiens (human)Potency22.3872AID588855
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.6741AID1645841
GVesicular stomatitis virusPotency0.7564AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency13.4504AID1645840
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.1259AID504332
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency8.9125AID743266
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency100.0000AID504891
gemininHomo sapiens (human)Potency20.5962AID624296
Glycoprotein hormones alpha chainHomo sapiens (human)Potency3.1623AID624291
Interferon betaHomo sapiens (human)Potency0.7564AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.7564AID1645842
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency39.8107AID720708
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.7564AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.7564AID1645842

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Cannabinoid receptor 1 (brain)Homo sapiens (human)IC5017.7000AID2822
cannabinoid receptor 2Homo sapiens (human)IC5032.0000AID2836
G-protein coupled receptor 35 isoform aHomo sapiens (human)IC5032.0000AID2815
G-protein coupled receptor 55Homo sapiens (human)IC502.6822AID2013; AID2820

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Cannabinoid receptor 1 (brain)Homo sapiens (human)EC5032.0000AID2814
cannabinoid receptor 2Homo sapiens (human)EC5032.0000AID2835
G-protein coupled receptor 35 isoform aHomo sapiens (human)EC5032.0000AID2809

Bioassays (12)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922		Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127		High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
ISSN: 1945-7170		A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922		Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127		High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922		Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127		High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
ISSN: 1945-7170		A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1285127Antagonist activity at HA-epitope tagged GRP55E expressed with GFP-tagged beta-arr2 in human U2OS cells assessed as LPI-stimulated redistribution of beta-arr2 preincubated for 15 mins by beta-arrestin translocation assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
ISSN: 1464-3405		Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones.

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's5 (55.56)24.3611
2020's3 (33.33)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
acetamide
0
acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia		00low000000
melatonin
0
acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger		00low000000
n-acetylserotonin
0
acetamides;
N-acylserotonin;
phenols		antioxidant;
human metabolite;
mouse metabolite;
tropomyosin-related kinase B receptor agonist		00low000000
acetanilide
0
acetamides;
anilide		analgesic00low000000
n'-acetylspermine
0
acetamides;
acetylspermine		human metabolite00low000000
6-chloromelatonin
0
acetamides00low000000
6-hydroxymelatonin
0
acetamides;
tryptamines		metabolite;
mouse metabolite		00low000000
acetaminophen
0
acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic		00low000000
acetarsol
0
acetamides;
anilide		00low000000
4-(acetylamino)benzeneacetic acid
0
acetamides;
anilide		00low000000
diatrizoic acid
0
acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic		00low000000
ci 994
0
acetamides;
benzamides;
substituted aniline		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor		00low000000
colchicine, (+-)-isomer
0
acetamides;
alkaloid;
aromatic ether;
carbotricyclic compound		microtubule-destabilising agent;
plant metabolite		00low000000
gr 89696
0
acetamides00low000000
guanfacine
0
acetamides00low000000
hexamethylene bisacetamide
0
acetamides00low000000
acecainide
0
acetamides;
benzamides		anti-arrhythmia drug00low000000
phenacemide
0
acetamides00low000000
phenacetin
0
acetamides;
aromatic ether		cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug		00low000000
practolol
0
acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist		00low000000
tropicamide
0
acetamides00low000000
talactoferrin alfa
0
acetamides00low000000
methacetin
0
acetamides;
aromatic ether		00low000000
acedapsone
0
acetamides;
anilide;
secondary carboxamide;
sulfone		antimalarial;
antimicrobial drug		00low000000
n-methylacetamide
0
acetamides;
monocarboxylic acid amide		metabolite00low000000
acetopyrrothine
0
acetamides;
dithiolopyrrolone antibiotic		angiogenesis inhibitor;
antibacterial agent;
antifungal agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite;
protein synthesis inhibitor;
toxin		00low000000
phenylbutyramide
0
acetamides00low000000
N-(2-methoxyphenyl)acetamide
0
acetamides;
methoxybenzenes		00low000000
4-methylacetanilide
0
acetamides;
toluenes		00low000000
arsthinol
0
acetamides;
anilide		00low000000
nithiamide
0
acetamides;
aromatic amide		00low000000
4'-(chloroacetyl)acetanilide
0
acetamides;
alpha-chloroketone;
aromatic ketone		00low000000
4-chloroacetanilide
0
acetamides;
monochlorobenzenes		00low000000
monoacetyldapsone
0
acetamides;
anilide;
secondary carboxamide;
sulfone		00low000000
2-hydroxyacetanilide
0
acetamides;
phenols		anti-inflammatory agent;
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
platelet aggregation inhibitor;
xenobiotic metabolite		00low000000
3-hydroxyacetanilide
0
acetamides;
phenols		non-narcotic analgesic00low000000
n-ethylacetamide
0
acetamidesmetabolite00low000000
ethyl n-alpha-acetyl-tyrosinate
0
acetamides;
ethyl ester;
L-tyrosine derivative;
phenols		00low000000
2-acetamidoethanethiol
0
acetamidesmetabolite00low000000
n,n-diethylphenylacetamide
0
acetamides00low000000
trimethylcolchicinic acid methyl ether
0
acetamides;
alkaloid;
carbotricyclic compound		00low000000
dimethylacetamide
0
acetamides;
monocarboxylic acid amide		human metabolite00low000000
4-acetylaminofluorene
0
acetamides;
fluorenes		mitogen00low000000
ioxitalamic acid
0
acetamides;
benzoic acids;
dicarboxylic acid monoamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic		00low000000
lorcainide
0
acetamides00low000000
bidisomide
0
acetamides00low000000
n(4)-acetylsulfadiazine
0
acetamides;
pyrimidines;
sulfonamide		marine xenobiotic metabolite00low000000
oseltamivir
0
acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic		00low000000
6-sulfatoxymelatonin
0
acetamides00low000000
n-acetylaminoantipyrine
0
acetamides;
pyrazoles		drug metabolite;
marine xenobiotic metabolite		00low000000
milnacipran
0
acetamides00low000000
N(4)-acetylsulfathiazole
0
1,3-thiazoles;
acetamides;
sulfonamide		marine xenobiotic metabolite00low000000
disobutamide
0
acetamides00low000000
glycolamide
0
acetamides00low000000
n-acetylhistamine
0
acetamides;
imidazoles		human metabolite00low000000
n-acetyltryptamine
0
acetamides;
indoles		00low000000
acamprosate
0
acetamides;
organosulfonic acid		environmental contaminant;
neurotransmitter agent;
xenobiotic		00low000000
guanfacine hydrochloride
0
acetamidesgeroprotector00low000000
epanolol
0
acetamides00low000000
N-Acetylhomoveratrylamine
0
acetamides00low000000
s20098
0
acetamides00low000000
acetaminophen sulfate ester
0
acetamides;
aryl sulfate		drug metabolite00low000000
acetaminophen mercapturate
0
acetamides;
organic sulfide;
phenols;
S-substituted N-acetyl-L-cysteine		drug metabolite;
human urinary metabolite;
rat metabolite		00low000000
4-(hydroxyphenyl)acetamide
0
acetamides00low000000
n-acetyltryptophanamide
0
acetamides;
L-tryptophan derivative;
primary carboxamide;
secondary carboxamide		00low000000
n-acetyldopamine
0
acetamides;
catechols;
N-(fatty acyl)-dopamine;
secondary carboxamide		human urinary metabolite;
marine metabolite		00low000000
ethyl-3-(n-n-butyl-n-acetyl)aminopropionate
0
acetamides;
ethyl ester;
tertiary carboxamide		00low000000
n-acetylcytidine
0
acetamides;
cytidines;
secondary carboxamide		metabolite00low000000
2-iodomelatonin
0
acetamides00low000000
n-acetyltyramine
0
acetamides;
tyramines		animal metabolite;
Aspergillus metabolite;
bacterial metabolite;
marine metabolite;
quorum sensing inhibitor		00low000000
luzindole
0
acetamides;
indoles		melatonin receptor antagonist00low000000
acetylphenylalanyl-prolyl-boroarginine
0
acetamides;
C-terminal boronic acid peptide;
guanidines		anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor		00low000000
n',n''-diacetylspermine
0
acetamides00low000000
bcx 1812
0
3-hydroxy monocarboxylic acid;
acetamides;
cyclopentanols;
guanidines		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor		00low000000
acetyltaurine
0
acetamides;
organosulfonic acid		human blood serum metabolite;
human urinary metabolite		00low000000
milnacipran hydrochloride
0
acetamides00low000000
n(4)-acetylsulfadimethoxine
0
acetamides;
pyrimidines;
sulfonamide		marine xenobiotic metabolite00low000000
monoacetylcadaverine
0
acetamides;
N-substituted cadaverine;
primary amino compound;
secondary carboxamide		human metabolite00low000000
N-hydroxy-2-phenylacetamide
0
acetamides00low000000
N-(1-phenylethyl)acetamide
0
acetamides;
secondary carboxamide		00low000000
gamma-lumicolchicine
0
acetamides;
alkaloid;
carbotricyclic compound		00low000000
1-(1-oxo-2-phenylethyl)-4-piperidinecarboxylic acid
0
acetamides00low000000
mr 16728
0
acetamides00low000000
linezolid
0
acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor		00low000000
ammodendrine
0
acetamides;
N-acylpiperidine;
piperidine alkaloid		plant metabolite;
teratogenic agent		00low000000
laninamivir
0
acetamides00low000000
N-[2-(4-methoxyphenyl)ethyl]acetamide
0
acetamides00low000000
N-(4-acetamidophenyl)-2-[(5-cyclopropyl-4-ethyl-1,2,4-triazol-3-yl)thio]acetamide
0
acetamides;
anilide		00low000000
N-(4-{[2-(pyridin-3-yl)piperidin-1-yl]sulfonyl}phenyl)acetamide
0
acetamides;
piperidines;
pyridines;
sulfonamide		00low000000
2-(4-methoxyphenyl)-N-(phenylmethyl)-N-propan-2-ylacetamide
0
acetamides00low000000
N-[4-(4-morpholinylazo)phenyl]acetamide
0
acetamides;
anilide		00low000000
N-[[6-cyano-5-(ethylamino)-3-methyl-2-pyrazinyl]methyl]-N-phenylacetamide
0
acetamides;
anilide		00low000000
N-[4-(5-bromo-2-thiophenyl)-2-thiazolyl]acetamide
0
acetamides;
aromatic amide		00low000000
1-(1-azepanyl)-2-(4-bromophenyl)ethanone
0
acetamides00low000000
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-nitrophenyl)acetamide
0
acetamides00low000000
N-(5-chloro-2-hydroxyphenyl)-2-(4-methoxyphenyl)acetamide
0
acetamides00low000000
N-[3-(methylthio)-1,2,4-thiadiazol-5-yl]-2-phenylacetamide
0
acetamides00low000000
2-(3-acetamidophenoxy)-N-phenylacetamide
0
acetamides;
anilide		00low000000
1-(4-methoxyphenyl)-N-(1,3,4-thiadiazol-2-yl)-1-cyclopentanecarboxamide
0
acetamides00low000000
N-[4-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide
0
acetamides;
anilide		00low000000
N-[4-[2-[(6-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide
0
acetamides;
anilide		00low000000
N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide
0
acetamides;
anilide		00low000000
1-[[2-(3-bromo-4-methoxyphenyl)-1-oxoethyl]amino]-3-phenylthiourea
0
acetamides00low000000
4-(2,4-dichlorophenyl)-2-[(1-oxo-2-phenylethyl)amino]-3-thiophenecarboxamide
0
acetamides00low000000
2-acetamido-5-propyl-3-thiophenecarboxamide
0
acetamides;
aromatic amide		00low000000
2-(4-methoxyphenyl)-N-[4-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]phenyl]acetamide
0
acetamides00low000000
2-(4-bromophenyl)-N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)acetamide
0
acetamides00low000000
N-[4-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]phenyl]-2-(2-methoxyphenyl)acetamide
0
acetamides00low000000
2-(4-chlorophenyl)-N-[4-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]phenyl]acetamide
0
acetamides00low000000
1-ethyl-3-[(1-oxo-2-phenylethyl)amino]thiourea
0
acetamides00low000000
N-[4-[[2-[1-(2-methoxyethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl]thio]phenyl]acetamide
0
acetamides;
anilide		00low000000
2-phenyl-N-[2-(phenylmethylthio)ethyl]acetamide
0
acetamides00low000000
N-[2-(4-tert-butylphenoxy)ethyl]-2-(4-fluorophenyl)acetamide
0
acetamides00low000000
2-(4-chlorophenyl)-N-[4-(difluoromethylthio)phenyl]acetamide
0
acetamides00low000000
N-(4-acetamidophenyl)-2-[5-(1-piperidinylsulfonyl)-2-thiophenyl]acetamide
0
acetamides;
anilide		00low000000
N-[4-[(2-furanylmethylamino)-sulfanylidenemethyl]phenyl]acetamide
0
acetamides;
anilide		00low000000
acetylthiourea
0
acetamides;
thioureas		00low000000
alpha-acetyllysine methyl ester
0
acetamides;
alpha-amino acid ester;
L-lysine derivative;
methyl ester;
primary amino compound		00low000000
1-(2,6-dimethyl-1-piperidinyl)-2-phenylethanone
0
acetamides00low000000
N-(2-methoxyphenyl)-2-phenyl-2-(phenylthio)acetamide
0
acetamides00low000000
ici 199441
0
acetamides00low000000
N-[4-[[2-(4-acetamidoanilino)-5-nitro-4-pyrimidinyl]amino]phenyl]acetamide
0
acetamides;
anilide		00low000000
1-[5-hydroxy-3-methyl-5-(3-pyridinyl)-4H-pyrazol-1-yl]-2-(4-methylphenyl)ethanone
0
acetamides00low000000
2-methoxy-N-[(4-methylphenyl)methyl]-2-phenylacetamide
0
acetamides00low000000
CID 3191469
0
acetamides;
anilide		anticoronaviral agent00low000000
CID 3198732
0
acetamides;
anilide		anticoronaviral agent00low000000
2-(4-ethoxyphenyl)-1-[5-hydroxy-3-methyl-5-(trifluoromethyl)-4H-pyrazol-1-yl]ethanone
0
acetamides00low000000
5-methoxycarbonylamino-n-acetyltryptamine
0
acetamides00low000000
2-(4-chlorophenyl)-3-methyl-N-(2-thiazolyl)butanamide
0
acetamides00low000000
N-[2-[1-(3,5-dimethyl-1-piperidinyl)-1-oxopropan-2-yl]oxyphenyl]acetamide
0
acetamides;
anilide		00low000000
brl 52537
0
acetamides00low000000
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(-)-isomer
0
acetamides00low000000
levomilnacipran
0
acetamides00low000000
andarine
0
acetamides;
anilide		00low000000
ro-28-1675
0
acetamides00low000000
holomycin
0
acetamides;
dithiolopyrrolone antibiotic		antibacterial agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite		00low000000
N-[1-(5,6-dicyano-3-methyl-2-pyrazinyl)ethyl]-N-phenylacetamide
0
acetamides;
anilide		00low000000
milnacipran
0
acetamides00low000000
trametinib
0
acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector		00low000000
n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine
0
acetamides00low000000
2-acetamidoglucal
0
acetamides;
glycal derivative		metabolite00low000000
3-[1-[[1-(4-methoxyphenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
0
acetamides00low000000
3-[1-[oxo-(1-phenylcyclopropyl)methyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
0
acetamides00low000000
3-[1-[[1-(4-chlorophenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
0
acetamides00low000000
n(alpha)-acetylfusarinines
0
2,5-diketopiperazines;
acetamides;
carboxylic ester;
homoallylic alcohol;
hydroxamic acid;
primary alcohol		siderophore00low000000
N-[2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenyl]acetamide
0
acetamides;
anilide		00low000000
N-[5-[[2-(4-acetamidoanilino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-3-methoxybenzamide
0
acetamides;
anilide		00low000000
N-[5-[[2-(4-acetamidoanilino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-5-bromo-2-furancarboxamide
0
acetamides;
anilide		00low000000
N-[(2S,3S)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
0
acetamides00low000000
KOM70144
0
acetamides;
benzamides;
naphthalenes;
secondary carboxamide		anticoronaviral agent;
protease inhibitor		00low000000
n-(2-(5-methoxy-2-oxo-2,3-dihydro-1h-indol-3-yl)ethyl)acetamide
0
acetamides;
hydroxyindoles;
tryptamines		antineoplastic agent;
apoptosis inducer;
plant metabolite		00low000000
N-[4-[2-(2-methoxyethylamino)-6H-1,3,4-thiadiazin-5-yl]phenyl]acetamide
0
acetamides;
anilide		00low000000
N-[4-[2-(2-oxolanylmethylamino)-6H-1,3,4-thiadiazin-5-yl]phenyl]acetamide
0
acetamides;
anilide		00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide
1
aromatic amide201620168.0high000010
2-furanyl-[4-(2-methyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]methanone
1
N-arylpiperazine201620168.0high000010
3-[1-[[1-(4-methoxyphenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
1
acetamides201620168.0high000010
3-[1-[oxo-(1-phenylcyclopropyl)methyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
1
acetamides201620168.0high000010
3-[1-[[1-(4-chlorophenyl)cyclopropyl]-oxomethyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
1
acetamides201620168.0high000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Congenital Zika Syndrome0
1
202020204.0medium000010
Disease Models, Animal0
1
202020204.0medium000010
Inflammation0
1
2010201014.0medium000100
Innate Inflammatory Response0
1
2010201014.0medium000100
Zika Virus Infection0
1
202020204.0medium000010

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019